Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc. (NASDAQ: INVA), will present new analyses from its zoliflodacin Phase 3 trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE